Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 8/2009

01.08.2009 | Original Article

Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches

verfasst von: Terry J. Fry, Jessica L. Shand, Matthew Milliron, Sarah K. Tasian, Crystal L. Mackall

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 8/2009

Einloggen, um Zugang zu erhalten

Abstract

Dendritic cells (DCs) serve as central regulators of adaptive immunity by presenting antigens and providing necessary co-signals. Environmental information received by the DCs determines the co-signals delivered to the responding adaptive cells and, ultimately, the outcome of the interaction. DCs loaded with relevant antigens have been used as therapeutic cellular vaccines, but the optimal antigen loading method has not been determined. We compared different methods to load class I and class II epitopes from the male antigenic complex, HY, onto DCs for the potency of the immune response induced in vivo. Co-incubation of female DCs with HY peptides, RNA or cell lysate from HY expressing tumor induced immune responses equivalent to male DCs. In contrast, female DCs incubated with irradiated, apoptotic HY expressing tumor cells (or male B cells) generated a stronger immune response than male DCs or female DCs loaded using any of the other methods. DC loading with apoptotic tumor resulted in complete protection against high dose HY-expressing tumor challenge whereas 100% lethality was observed in groups receiving DCs that were loaded with peptides, RNA, or lysate. We conclude that signals provided to the DCs by apoptotic cells substantially augment the potency of DC vaccines.
Literatur
1.
Zurück zum Zitat Mellman I, Steinman RM (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106:255–258PubMedCrossRef Mellman I, Steinman RM (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106:255–258PubMedCrossRef
2.
Zurück zum Zitat Dubsky P, Ueno H, Piqueras B, Connolly J, Banchereau J, Palucka AK (2005) Human dendritic cell subsets for vaccination. J Clin Immunol 25:551–572PubMedCrossRef Dubsky P, Ueno H, Piqueras B, Connolly J, Banchereau J, Palucka AK (2005) Human dendritic cell subsets for vaccination. J Clin Immunol 25:551–572PubMedCrossRef
3.
Zurück zum Zitat Gallucci S, Lolkema M, Matzinger P (1999) Natural adjuvants: endogenous activators of dendritic cells. Nat Med 5:1249–1255PubMedCrossRef Gallucci S, Lolkema M, Matzinger P (1999) Natural adjuvants: endogenous activators of dendritic cells. Nat Med 5:1249–1255PubMedCrossRef
4.
Zurück zum Zitat Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987–995PubMedCrossRef Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987–995PubMedCrossRef
5.
Zurück zum Zitat Steinman RM, Pope M (2002) Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109:1519–1526PubMed Steinman RM, Pope M (2002) Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109:1519–1526PubMed
6.
Zurück zum Zitat Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089–3094PubMedCrossRef Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089–3094PubMedCrossRef
7.
Zurück zum Zitat Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915PubMedCrossRef Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915PubMedCrossRef
8.
Zurück zum Zitat Osada T, Clay TM, Woo CY, Morse MA, Lyerly HK (2006) Dendritic cell-based immunotherapy. Int Rev Immunol 25:377–413PubMedCrossRef Osada T, Clay TM, Woo CY, Morse MA, Lyerly HK (2006) Dendritic cell-based immunotherapy. Int Rev Immunol 25:377–413PubMedCrossRef
9.
Zurück zum Zitat Jackson SH, Alicea C, Owens JW, Eigsti CL, Malech HL (2002) Characterization of an early dendritic cell precursor derived from murine lineage-negative hematopoietic progenitor cells. Exp Hematol 30:430–439PubMedCrossRef Jackson SH, Alicea C, Owens JW, Eigsti CL, Malech HL (2002) Characterization of an early dendritic cell precursor derived from murine lineage-negative hematopoietic progenitor cells. Exp Hematol 30:430–439PubMedCrossRef
10.
Zurück zum Zitat Melchionda F, McKirdy MK, Medeiros F, Fry TJ, Mackall CL (2004) Escape from immune surveillance does not result in tolerance to tumor-associated antigens. J Immunother 27:329–338PubMedCrossRef Melchionda F, McKirdy MK, Medeiros F, Fry TJ, Mackall CL (2004) Escape from immune surveillance does not result in tolerance to tumor-associated antigens. J Immunother 27:329–338PubMedCrossRef
11.
Zurück zum Zitat Fields RC, Shimizu K, Mule JJ (1998) Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 95:9482–9487PubMedCrossRef Fields RC, Shimizu K, Mule JJ (1998) Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 95:9482–9487PubMedCrossRef
12.
Zurück zum Zitat Melchionda F, Fry TJ, Milliron MJ, McKirdy MA, Tagaya Y, Mackall CL (2005) Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest 115:1177–1187PubMed Melchionda F, Fry TJ, Milliron MJ, McKirdy MA, Tagaya Y, Mackall CL (2005) Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest 115:1177–1187PubMed
13.
Zurück zum Zitat O’Neill DW, Adams S, Bhardwaj N (2004) Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104:2235–2246PubMedCrossRef O’Neill DW, Adams S, Bhardwaj N (2004) Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104:2235–2246PubMedCrossRef
14.
Zurück zum Zitat Scott DM, Ehrmann IE, Ellis PS, Chandler PR, Simpson E (1997) Why do some females reject males? The molecular basis for male-specific graft rejection. J Mol Med 75:103–114PubMedCrossRef Scott DM, Ehrmann IE, Ellis PS, Chandler PR, Simpson E (1997) Why do some females reject males? The molecular basis for male-specific graft rejection. J Mol Med 75:103–114PubMedCrossRef
15.
Zurück zum Zitat Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM (2002) Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 196:1091–1097PubMedCrossRef Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM (2002) Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 196:1091–1097PubMedCrossRef
16.
Zurück zum Zitat Krysko DV, D’Herde K, Vandenabeele P (2006) Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 11:1709–1726PubMedCrossRef Krysko DV, D’Herde K, Vandenabeele P (2006) Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 11:1709–1726PubMedCrossRef
17.
Zurück zum Zitat Ferguson TA, Kazama H (2005) Signals from dying cells: tolerance induction by the dendritic cell. Immunol Res 32:99–108PubMedCrossRef Ferguson TA, Kazama H (2005) Signals from dying cells: tolerance induction by the dendritic cell. Immunol Res 32:99–108PubMedCrossRef
18.
Zurück zum Zitat Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N (2000) Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191:423–434PubMedCrossRef Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N (2000) Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191:423–434PubMedCrossRef
19.
Zurück zum Zitat Steinman RM, Turley S, Mellman I, Inaba K (2000) The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 191:411–416PubMedCrossRef Steinman RM, Turley S, Mellman I, Inaba K (2000) The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 191:411–416PubMedCrossRef
20.
Zurück zum Zitat Morelli AE (2006) The immune regulatory effect of apoptotic cells and exosomes on dendritic cells: its impact on transplantation. Am J Transplant 6:254–261PubMedCrossRef Morelli AE (2006) The immune regulatory effect of apoptotic cells and exosomes on dendritic cells: its impact on transplantation. Am J Transplant 6:254–261PubMedCrossRef
21.
Zurück zum Zitat Nowak AK, Lake RA, Marzo AL et al (2003) Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170:4905–4913PubMed Nowak AK, Lake RA, Marzo AL et al (2003) Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170:4905–4913PubMed
22.
Zurück zum Zitat Ronchetti A, Rovere P, Iezzi G et al (1999) Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J Immunol 163:130–136PubMed Ronchetti A, Rovere P, Iezzi G et al (1999) Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J Immunol 163:130–136PubMed
23.
Zurück zum Zitat Schaible UE, Winau F, Sieling PA et al (2003) Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 9:1039–1046PubMedCrossRef Schaible UE, Winau F, Sieling PA et al (2003) Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 9:1039–1046PubMedCrossRef
24.
Zurück zum Zitat Albert ML, Sauter B, Bhardwaj N (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86–89PubMedCrossRef Albert ML, Sauter B, Bhardwaj N (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86–89PubMedCrossRef
25.
Zurück zum Zitat Russo V, Tanzarella S, Dalerba P et al (2000) Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc Natl Acad Sci USA 97:2185–2190PubMedCrossRef Russo V, Tanzarella S, Dalerba P et al (2000) Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc Natl Acad Sci USA 97:2185–2190PubMedCrossRef
26.
Zurück zum Zitat Ferguson TA, Herndon J, Elzey B, Griffith TS, Schoenberger S, Green DR (2002) Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8(+) T cells produce active immune unresponsiveness. J Immunol 168:5589–5595PubMed Ferguson TA, Herndon J, Elzey B, Griffith TS, Schoenberger S, Green DR (2002) Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8(+) T cells produce active immune unresponsiveness. J Immunol 168:5589–5595PubMed
27.
Zurück zum Zitat Obeid M, Panaretakis T, Joza N et al (2007) Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 14:1848–1850PubMedCrossRef Obeid M, Panaretakis T, Joza N et al (2007) Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 14:1848–1850PubMedCrossRef
28.
Zurück zum Zitat Casares N, Pequignot MO, Tesniere A et al (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202:1691–1701PubMedCrossRef Casares N, Pequignot MO, Tesniere A et al (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202:1691–1701PubMedCrossRef
Metadaten
Titel
Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches
verfasst von
Terry J. Fry
Jessica L. Shand
Matthew Milliron
Sarah K. Tasian
Crystal L. Mackall
Publikationsdatum
01.08.2009
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 8/2009
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-008-0638-7

Weitere Artikel der Ausgabe 8/2009

Cancer Immunology, Immunotherapy 8/2009 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.